Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail

Novartis AG plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.